Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, andAstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Awiqli, insulinicodec, Novo Nordisk, FDA approval, once-weekly insulin, diabetes, Novartis, Excellergy, Xolair, Otsuka, Transcend Therapeutics, PTSD, neuropsychiatry, CVCCapital, Recordati, AstraZeneca, tozorakimab, COPD, Rocket Pharmaceuticals,KRESLADI, gene therapy, LAD-I, Sarclisa, Sanofi, CHMP, M&A, deals, Lilly, J&J, GSK